| 1423 |
National Cancer Institute |
Html |
en |
Oral Cavity and Oropharyngeal Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing cancer of the lip or mouth and about approaches that may help in the prevention of this disease. |
| large cohort study | 0.376766 |
| oral cavity accounts | 0.552607 |
| Papua New Guinea | 0.380571 |
| French Guiana | 0.34684 |
| United States | 0.44201 |
| age-adjusted incidence | 0.362072 |
| 100,000 | 0.359624 |
| areca nut. | 0.346627 |
| high alcohol intake | 0.39156 |
| epidemiologic studies | 0.378316 |
| oropharyngeal cancers | 0.387229 |
| 5-year survival rate | 0.495328 |
| oropharyngeal cancer. | 0.45765 |
| personal history | 0.348827 |
| Human papillomavirus | 0.350206 |
| oral cavity cancer | 0.797428 |
| future primary cancer | 0.407597 |
| betel quid | 0.499314 |
| tobacco | 0.395457 |
| stage-specific survival rates | 0.38041 |
| important risk factor | 0.379095 |
| World Standard Population | 0.382887 |
| regional lymph node | 0.379129 |
| U.S. incidence | 0.3611 |
|
| worldwide incidence rate | 0.411302 |
| Squamous cell carcinoma | 0.382371 |
| risk factors | 0.357771 |
| elevated risk | 0.400796 |
| betel-quid chewing | 0.354181 |
| distinct diseases | 0.351665 |
| relative risk | 0.346929 |
| mortality rate | 0.410597 |
| common pharyngeal cancer. | 0.386214 |
| pharynx cancer | 0.364625 |
| persons | 0.372394 |
| Gutka chewing | 0.349427 |
| commonly available forms | 0.391505 |
| smokeless tobacco | 0.374103 |
| oral mucosal | 0.411667 |
| high risk | 0.355532 |
| neck region | 0.347305 |
| oral cavity | 0.982405 |
| oropharyngeal cancer | 0.482897 |
| mortality estimates | 0.39101 |
| added tobacco | 0.357539 |
| betel leaf | 0.365996 |
| mortality rates | 0.364344 |
|
CLICK HERE |
| 1736 |
National Cancer Institute |
Html |
en |
Surgery to Reduce the Risk of Breast Cancer |
A fact sheet that describes mastectomy and salpingo-oophorectomy, two surgeries that may be used to reduce breast cancer risk in women at very high risk, and nonsurgical options. |
| Surgical Adjuvant Breast | 0.509427 |
| breast cancer talk | 0.520216 |
| primary breast cancer | 0.51166 |
| breast reconstruction surgery | 0.528802 |
| radiation-associated breast cancer | 0.517996 |
| breast health specialist | 0.49326 |
| Breast cancer phenotype | 0.510792 |
| Breast Cancer Research | 0.511066 |
| early-stage breast cancer | 0.509281 |
| breast screening | 0.478516 |
| cancer risk reduction | 0.514817 |
| bilateral risk-reducing mastectomy | 0.474208 |
| bilateral breast cancer | 0.543505 |
| ovarian cancer | 0.506899 |
| frequent breast cancer | 0.518031 |
| clinical breast examinations | 0.496735 |
| normal breast functions | 0.496662 |
| high risk | 0.488512 |
| invasive breast cancer | 0.560151 |
| Clinical Oncology | 0.486116 |
| primary breast cancers | 0.493314 |
| BRCA2 mutation carriers | 0.492894 |
| contralateral breast cancer | 0.595168 |
| women | 0.553369 |
|
| early breast cancer | 0.515841 |
| J. Prophylactic mastectomy | 0.474619 |
| appropriate cancer prevention | 0.465287 |
| prophylactic bilateral mastectomy | 0.491713 |
| breast cancer susceptibility | 0.516869 |
| breast cancer surgery | 0.554904 |
| prophylactic surgery | 0.485463 |
| breast cancers | 0.51424 |
| greatest breast cancer | 0.535025 |
| breast tissue | 0.513481 |
| Cancer Risk Assessment | 0.465659 |
| ovarian cancer risk | 0.465289 |
| breast surgeons | 0.489292 |
| postmenopausal women | 0.468075 |
| breast cancer risk | 0.685989 |
| breast cancer | 0.963464 |
| bilateral prophylactic mastectomy | 0.680206 |
| Breast Cancer Trialists | 0.509574 |
| prophylactic mastectomy | 0.701891 |
| Bilateral prophylactic salpingo-oophorectomy | 0.47763 |
| contralateral prophylactic mastectomy | 0.553604 |
| strong family history | 0.509663 |
| breast cancer-associated mutations | 0.511851 |
| et al | 0.584443 |
|
CLICK HERE |
| 1774 |
National Cancer Institute |
Html |
es |
Fatiga (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de la fatiga, una afección caracterizada por extremo cansancio e incapacidad para funcionar por la falta de energía, que a menudo se observa como una complicación del cáncer y su tratamiento. |
| adjuvant chemotherapy | 0.23884 |
| Cancer patients as | 0.267855 |
| cáncer respalda | 0.229838 |
| Breitbart W | 0.226519 |
| frase cansancio | 0.380985 |
| cancer-related fatigue | 0.694477 |
| Fosså SD | 0.231004 |
| critical appraisal | 0.229895 |
| Nail LM | 0.242438 |
| tripart assessment survey | 0.229866 |
| Fatigue Coalition | 0.248097 |
| Sin embargo | 0.226985 |
| Bower JE | 0.361676 |
| National Comprehensive Cancer | 0.433137 |
| Supportive Oncology | 0.240439 |
| Jacobsen PB | 0.225244 |
| Cancer Res | 0.298674 |
| Fatigue after treatment | 0.230762 |
| Radiat Oncol Biol | 0.235818 |
| Supportive Oncology Updates | 0.236977 |
| Hematol Oncol Clin | 0.226159 |
| Fatigue Symptom Inventory | 0.230776 |
| Support Care | 0.298981 |
| Ganz PA | 0.346159 |
| survivors with persistent | 0.230866 |
|
| Comprehensive Cancer Network | 0.433487 |
| patients with | 0.336679 |
| Donovan KA | 0.225133 |
| Pain Symptom Manage | 0.518651 |
| Cella D | 0.246025 |
| patients treated with | 0.224435 |
| Ancoli-Israel S | 0.229262 |
| Oncol Nurs Forum | 0.973332 |
| citocinas proinflamatorias | 0.262356 |
| Care Cancer | 0.446044 |
| Portenoy RK | 0.231388 |
| Procrit Study Group | 0.227164 |
| menor cansancio | 0.370471 |
| breast carcinoma survivors | 0.265734 |
| patients receiving | 0.226133 |
| Clin Oncol | 0.504505 |
| Oncol Biol Phys | 0.236851 |
| individual with | 0.229384 |
| research literature investigating | 0.225358 |
| long-term breast carcinoma | 0.246503 |
| early stage breast | 0.235969 |
| Lee Fatigue Scale | 0.226512 |
| cancer patient | 0.800328 |
| término cansancio | 0.373768 |
|
CLICK HERE |
| 1838 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de testículo (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de testículo. |
| Warde P | 0.218827 |
| Compton CC | 0.2177 |
| Belt-Dusebout AW | 0.219564 |
| Cancer Collaborative Group | 0.22935 |
| Fosså SD | 0.255716 |
| germ cell tumor | 0.301479 |
| testicular cancer | 0.813967 |
| Sin embargo | 0.218866 |
| 7th ed | 0.217529 |
| germ cell tumours | 0.262155 |
| Cell Cancer Collaborative | 0.240371 |
| cell testicular tumors | 0.220056 |
| testicular malignant germ | 0.217591 |
| tumor markers | 0.216572 |
| International Germ Cell | 0.302822 |
| Natl Cancer Inst | 0.334587 |
| second cancers | 0.223863 |
| contralateral testicular germ | 0.218168 |
| cell tumor patients | 0.216601 |
| Testicular Cancer Study | 0.224272 |
| patients with | 0.222118 |
| testicular intraepithelial neoplasia | 0.225067 |
| with testicular germ | 0.235317 |
| Eur Urol | 0.215174 |
| Urol Clin North | 0.219868 |
|
| testicular seminoma | 0.246035 |
| Germ Cell Consensus | 0.24481 |
| Cell Cancer Consensus | 0.272426 |
| >2 cm | 0.228724 |
| Cancer Staging Manual | 0.263147 |
| European Germ Cell | 0.228106 |
| germ cell | 0.993431 |
| nonseminomatous germ | 0.23506 |
| cicatriz histológica testicular | 0.215529 |
| Clin Oncol | 0.466287 |
| saco vitelino | 0.231013 |
| Clin North Am | 0.217469 |
| estadio iii | 0.231852 |
| clinical stage | 0.215125 |
| Cell Consensus Classification | 0.239173 |
| Byrd DR | 0.216367 |
| testicular germ-cell tumours | 0.215172 |
| cancer consensus group | 0.233559 |
| germ cell testis | 0.214767 |
| germ cell cancer | 0.692466 |
| Children's Cancer Study | 0.215431 |
| testicular germ | 0.280501 |
| Cancer Study Group | 0.229234 |
| AJCC Cancer Staging | 0.265329 |
|
CLICK HERE |
| 1919 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer primario de hígado en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer primario de hígado en adultos. |
| pequeñas incisiones | 0.360209 |
| Cirujano oncólogo | 0.35403 |
| Clinic Liver Cancer | 0.895614 |
| siguientes procedimientos | 0.409083 |
| siguientes aspectos | 0.386863 |
| pequeña cantidad | 0.337477 |
| tratamiento causa | 0.413554 |
| siguientes métodos | 0.411504 |
| siguientes especialistas | 0.376622 |
| rayos x | 0.47678 |
| imagen tridimensional 3-D | 0.372363 |
| lesiones duraderas | 0.36475 |
| sustancias dañinas | 0.379531 |
| cuerpo usa | 0.466772 |
| ondas sonoras | 0.366833 |
|
| triple fase | 0.491781 |
| National Cancer Institute | 0.334891 |
| siguientes riesgos | 0.332851 |
| sección superior derecha | 0.425641 |
| Instituto Nacional | 0.432945 |
| siguientes grupos | 0.397061 |
| PDQ Tratamiento | 0.382467 |
| siguientes puntos | 0.412752 |
| estadificación barcelona clinic | 0.916026 |
| hepatitis c | 0.503388 |
| Drugs Approved | 0.34614 |
| Physician Data Query | 0.434214 |
| Barcelona Clinic Liver | 0.903635 |
| pequeña incisión | 0.343621 |
| siguientes enlaces | 0.343192 |
|
CLICK HERE |
| 1960 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma uterino (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma uterino. |
| estadios iva | 0.401059 |
| sarcoma uterino causa | 0.406591 |
| siguientes procedimientos | 0.403992 |
| Estadio IA | 0.402022 |
| estadio iv | 0.408854 |
| cáncer.ampliar cistoscopia | 0.401375 |
| siguientes aspectos | 0.404454 |
| Estadio IB | 0.402046 |
| estadio ii | 0.409805 |
| útero forma | 0.405141 |
| Estadio IIIB | 0.402011 |
| Estadio IIIC | 0.402019 |
| estadios ia | 0.401093 |
| vÃa oral | 0.40093 |
| Estadio IIIA | 0.402062 |
| rayos x | 0.401181 |
| ondas sonoras | 0.401284 |
|
| National Cancer Institute | 0.400945 |
| estadios iiia | 0.401156 |
| siguientes riesgos | 0.400687 |
| áreas anormales.ampliar examen | 0.402099 |
| Instituto Nacional | 0.401682 |
| PDQ Tratamiento | 0.411733 |
| ecograma.ampliar ecografÃa | 0.401623 |
| Physician Data Query | 0.403425 |
| último panel | 0.401341 |
| estadio iii | 0.406282 |
| cuello uterino | 0.559914 |
| histerectomÃa abdominal | 0.405298 |
| sarcoma uterino | 0.996876 |
| cáncer quizás | 0.40452 |
| Estadio IVB | 0.402 |
| Estadio IVA | 0.401945 |
| extirpa tanta masa | 0.402241 |
|
CLICK HERE |
| 1965 |
National Cancer Institute |
Html |
es |
Tratamiento del tumor de Wilms y otros tumores renales infantiles (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del tumor de Wilms y otros tumores renales infantiles. |
| carcinoma mioepitelial renal | 0.526401 |
| siguientes procedimientos | 0.505279 |
| siguientes aspectos | 0.505599 |
| efectos secundarios meses | 0.505495 |
| siguientes sÃndromes | 0.506829 |
| siguientes razones | 0.503795 |
| rayos x | 0.510267 |
| niño ayuda | 0.504738 |
| estadio v | 0.504623 |
| tumores benignos | 0.514918 |
| sustancia llamada gadolinio | 0.50702 |
| tumores renales | 0.951588 |
| tumor renal | 0.637779 |
| pelvis renal | 0.507303 |
| alta potencia | 0.509261 |
| cánceres renales | 0.508824 |
| siguientes enfermedades | 0.50611 |
| nefroblastomatosis perilobular hiperplásica | 0.509412 |
| Antecedentes familiares | 0.504021 |
| vejiga almacena | 0.505429 |
| siguientes estadios | 0.504745 |
| riñón.ampliar ecografÃa | 0.506308 |
| células madre | 0.544993 |
| problemas renales | 0.514442 |
|
| adultos jóvenes | 0.513748 |
| estadio iv | 0.508345 |
| cabo ensayos | 0.506023 |
| cuerpo.ampliar anatomÃa | 0.504995 |
| pequeña cantidad | 0.51696 |
| estadio ii | 0.508321 |
| túbulos renales | 0.518212 |
| ondas sonoras | 0.510366 |
| efectos tardÃos | 0.540359 |
| escáner.ampliar exploración | 0.503685 |
| PDQ Efectos tardÃos | 0.519051 |
| Von Hippel-Lindau | 0.513101 |
| PDQ Tratamiento | 0.517805 |
| determinados cambios | 0.504218 |
| nefroma mesoblástico congénito | 0.582259 |
| siguientes signos | 0.506344 |
| tirosina cinasa | 0.506394 |
| siguientes factores | 0.505365 |
| siguientes situaciones | 0.504547 |
| gen smarcb1 | 0.504862 |
| células renales | 0.823203 |
| Wilms Tumor | 0.52815 |
| gran crecimiento | 0.51167 |
| Childhood Kidney Cancers | 0.504322 |
|
CLICK HERE |
| 2104 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de endometrio (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de endometrio y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| Surgical Adjuvant Breast | 0.312551 |
| Obstet Gynecol | 0.324802 |
| accessed july | 0.303593 |
| Iowa Women Health | 0.308818 |
| population-based case-control study | 0.304331 |
| available online | 0.305054 |
| Cancer Research Fund | 0.306547 |
| endometrial carcinoma | 0.319197 |
| Breast feeding practices | 0.304731 |
| American Cancer Society | 0.323044 |
| Prospective Investigation into | 0.30657 |
| Disease Control | 0.304429 |
| case-control study | 0.307735 |
| intentional weight loss | 0.305807 |
| risk factors | 0.315161 |
| colorectal cancer | 0.312231 |
| Cancer Causes Control | 0.326606 |
| Natl Cancer Inst | 0.357685 |
| Women's Health Study | 0.306339 |
| Women's Health Initiative | 0.307967 |
| PDQ Prevención | 0.303492 |
| Research On Cancer | 0.312008 |
| endometrial hyperplasia | 0.31494 |
| endometrial cancer | 0.992212 |
| Reproductive risk factors | 0.308365 |
|
| European Prospective Investigation | 0.306481 |
| investigation into cancer | 0.322236 |
| Women's Health | 0.310973 |
| endometrial cancer risk | 0.612217 |
| Cancer Facts | 0.307157 |
| Bowel Project | 0.305155 |
| Health Study | 0.307565 |
| Nutr Cancer | 0.307216 |
| dose-response meta-analysis | 0.303563 |
| Cancer Research | 0.309943 |
| National Cancer Institute | 0.30655 |
| epidemiological studies | 0.307756 |
| replacement therapy | 0.303602 |
| Breast Cancer Prevention | 0.308767 |
| endometrial carcinoma among | 0.306561 |
| Clin Oncol | 0.303952 |
| breast cancer | 0.379165 |
| systematic review | 0.305375 |
| PDQ Genetics | 0.303535 |
| physical activity | 0.307794 |
| Gynecol Cancer | 0.308219 |
| Breast Cancer Study | 0.308595 |
| National Surgical Adjuvant | 0.309763 |
| Women’s Health | 0.303756 |
|
CLICK HERE |
| 3656 |
National Cancer Institute |
Html |
en |
David Q. Matus, Ph.D. |
David Matus studies cellular invasion--a characteristic behavior of metastatic cancer cells--in an evolutionary context. |
| colon carcinoma cells | 0.575003 |
| anchor cell invasion | 0.641108 |
| basement membrane | 0.798484 |
| transcription factors | 0.55171 |
| cell lines | 0.544877 |
| Martindale lab | 0.540411 |
| cellular basement membrane | 0.610463 |
| basement membranes | 0.590872 |
| anchor cell | 0.729012 |
| reproductive tract | 0.559366 |
| graduate school | 0.537018 |
| invasion process | 0.549999 |
| deep evolutionary roots | 0.554576 |
| different nematode species | 0.556072 |
| small translucent worm | 0.572459 |
| sea anemones | 0.537853 |
| Dr. Matus | 0.992838 |
| independent research careers | 0.559323 |
| genetic control | 0.536692 |
| dense sheet-like layer | 0.561929 |
| connective tissue underneath | 0.560757 |
| —a systematic method | 0.560107 |
| uterine cells | 0.552149 |
| Caenorhabditis elegans | 0.544264 |
| basic biological processes | 0.563833 |
|
| scientist—while training dolphins | 0.567297 |
| evolutionary developmental biology | 0.55366 |
| vulval cells | 0.554372 |
| academic lineage—a trace | 0.553945 |
| individual genes | 0.558466 |
| Mark Q. Martindale | 0.628065 |
| science fair project | 0.55475 |
| Stony Brook University | 0.569431 |
| metastatic cancer cells | 0.596221 |
| mitotic cells | 0.54782 |
| scientific career—and | 0.537464 |
| anchor cell dividing | 0.581016 |
| invasive cell | 0.543064 |
| programmed cell death | 0.577561 |
| normal cells | 0.556326 |
| New York | 0.537757 |
| C. elegans | 0.565408 |
| anchor cell invasion—and | 0.584387 |
| David Q. Matus | 0.656523 |
| Cell Biology Department | 0.584431 |
| cellular invasion | 0.583572 |
| potential drug targets | 0.557542 |
| cell behaviors | 0.541546 |
| Dr. Martindale | 0.549501 |
|
CLICK HERE |
| 4330 |
National Cancer Institute |
Html |
en |
Screening Tests |
Information about tests that may be used to screen for cancer in people without symptoms of disease. |
| Breast Cancer Screening | 0.406484 |
| health care provider | 0.30932 |
| expert groups | 0.265652 |
| Cancer Screening summary | 0.902327 |
| fact sheet | 0.466524 |
| occult blood tests | 0.269438 |
| Mammograms fact sheet | 0.267038 |
| Detect Colorectal Cancer | 0.350233 |
| Prostate Cancer Screening | 0.306727 |
| health care providers | 0.256913 |
| PDQ® Breast Cancer | 0.380619 |
| Cancer Risk | 0.261618 |
| transvaginal ultrasound | 0.266045 |
| Ovarian Cancer Screening | 0.355679 |
| colorectal cancer | 0.408815 |
| routine PSA testing | 0.258642 |
| test | 0.313731 |
| Genetic Testing fact | 0.262194 |
| Skin Cancer Screening | 0.305113 |
| heavy smokers ages | 0.262129 |
| Colorectal Cancer Screening | 0.370971 |
| high risk | 0.258361 |
| Testing fact sheet | 0.311925 |
| Endometrial Cancer Screening | 0.308488 |
|
| Breast MRI | 0.244315 |
| Cervical Cancer Screening | 0.31686 |
| women | 0.251835 |
| imaging test | 0.262647 |
| digital rectal exam | 0.25607 |
| prostate cancer deaths | 0.288964 |
| helical computed tomography | 0.266342 |
| Clinical breast exams | 0.268026 |
| PDQ® Colorectal Cancer | 0.346246 |
| HPV Testing fact | 0.264281 |
| Polyps fact sheet | 0.318987 |
| effective ovarian cancer | 0.290042 |
| Lung Cancer Screening | 0.320215 |
| regular breast self-exams | 0.270315 |
| Melanoma fact sheet | 0.258634 |
| National Lung Screening | 0.295693 |
| Alpha-fetoprotein blood test | 0.268207 |
| PDQ® Ovarian Cancer | 0.331871 |
| blood test | 0.291254 |
| lung cancer deaths | 0.300295 |
| Test fact sheet | 0.267108 |
| information | 0.299153 |
| risk | 0.28214 |
| liver cancer | 0.25618 |
|
CLICK HERE |